ALPN News and Press, Alpine Immune Sciences Inc. From 03/16/23

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highli...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2022 financial results on Thursday, March 23, 202...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will participate in two upcoming healthcare conferences. Tuesday, March 7 th at 10:30am ET/7:30am PT, the C...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will present a corporate overview and host investor meetings at the SVB Securities Global...

Summary Vera Therapeutics has released an updated interim PP analysis on the phase 2b ORIGIN trial. The updated data excluded 14 patients who had some degree of a trial protocol violation, further enriching the data. The PP data was better than ITT data, where 36 weeks of data of th...

The shares of oncology-focused biotech Alpine Immune Sciences ( NASDAQ: ALPN ) gained Thursday after Morgan Stanley initiated its coverage with an Overweight recommendation citing its lead program ALPN-303, targeted at autoimmune and inflammatory indications. The analyst Michael E Ulz...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will participate in a fireside chat at the 5 th Annual Evercore ISI Healt...

Alpine Immune Sciences, Inc. (ALPN) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng - President, Head of R&D Andrew Sandler - CMO Paul Ricke...

Alpine Immune Sciences press release ( NASDAQ: ALPN ): Q3 GAAP EPS of -$0.42 misses by $0.32 . Revenue of $8.37M (-1.8% Y/Y) misses by $10.31M . As of September 30, 2022, Alpine’s cash, cash equivalents, restricted cash, and investments totaled $277.1 mi...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30...